Figure 1.

Simultaneous tumor and effector profiling to elucidate determinants of response and resistance post CD19-CAR T cell therapy in lymphoma

Simultaneous tumor and effector profiling (STEP) includes analysis of immune cells (circulating tumor DNA [ctDNA], cell-free CD19-CAR retroviral fragments [cfCD19-CAR], cell free T-cell receptor [cfTCR] rearrangements), tumor cells (bulk RNA-seq, SCNA), and the TME (e.g., CIBERSORTx). For details see text. CART: CD19-CAR T cells; LBCL: large B cell lymphoma; SCNA: somatic copy number alteration; TME: tumor microenvironment; Tu: tumor cells.